References
- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Ca Cancer J Clin. 2016;66:115–132.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;60:277–300.
- Wade J, Smith H, Hankins M, et al. Conducting oral examinations for cancer in general practice: what are the barriers. Fam Pract. 2010;27:77–84.
- Patel SC, Carpenter WR, Tyree S, et al. Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. JCO. 2011;29:1488–1494.
- Jeon JH, Min GK, Park JY, et al. Analysis of the outcome of young age tongue squamous cell carcinoma. Maxillofac Plast Reconstr Surg. 2017;39:41–48.
- Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–121.
- Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the national cancer institute cooperative research and development studies. Oncologist. 2001;6:22–28.
- Hussein MA, Saleh M, Ravandi F, et al. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2004;125:470–476.
- Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011;121:148–160.
- Xia J, Li Y, Yang Q, et al. Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. IJMS. 2012;13:9627–9641.
- Gao JK, Wang LX, Long B, et al. Arsenic trioxide inhibits cell growth and invasion via down- regulation of skp2 in pancreatic cancer cells. Asian Pac J Cancer Prev. 2015;16:3805–3810.
- Nakamura S, Nagano S, Nagao H, et al. Arsenic trioxide prevents osteosarcoma growth by inhibition of gli transcription via DNA damage accumulation. PLoS One. 2013;8:e69466.
- Peng Y, Kang Q, Luo Q, et al. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem. 2004;279:32941–32949.
- Tajima K, Terai S, Takami T, et al. Importance of inhibitor of DNA binding/differentiation 2 in hepatic stellate cell differentiation and proliferation. Hepatol Res. 2007;37:647–655.
- Peretz Y, Wu H, Patel S, et al. Inhibitor of DNA binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells. Plos One. 2015;10:e0116839.
- Yu X, Xu X, Han B, et al. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation. Pathol Oncol Res. 2009;15:91–96.
- Kubelac MP, Fetica B, Vlad IC, et al. The role of inhibitor of DNA-binding 1 (ID-1) protein and angiogenesis in serous ovarian cancer. Anticancer Res. 2014;34:413–416.
- Li W, Zhang CH, Hong YL, et al. Inhibitor of DNA-binding-1/inhibitor of differentiation-1 (ID-1) is implicated in various aspects of gastric cancer cell biology. Mol Biol Rep. 2012;39:3009–3015.
- Lai X, Liao J, Lin W, et al. Inhibitor of DNA-binding protein 1 knockdown arrests the growth of colorectal cancer cells and suppresses hepatic metastasis in vivo. Oncol Rep. 2014;32:79–88.
- Kim H, Chung H, Kim HJ, et al. Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells. Breast Cancer Res Treat. 2008;112:287–296.